Redmond, Wash.—November 1, 2002—ProCyte Corporation (OTCBB: PRCY.OB), a company whose patented GHK and AHK Copper Peptide technology is being used in a broadening array of consumer and medical-related products for skin care, hair care and tissue repair, today announced that it ranked number 344 on the 2002 Deloitte & Touche Technology Fast 500, a ranking of the 500 fastest growing technology companies in North America. Rankings are based on percentage revenue growth over five years, from 1997-2001. ProCyte grew 991 percent during this period.

ProCyte Chairman and Chief Executive Officer Jack Clifford said, "Despite a very difficult global economic environment, our company recently reported record financial results, marking its third consecutive quarter of profitability after nearly 17 years of research and development. We are very proud of our accomplishments and gratified to be ranked among an enviable class of highly respected companies."

"With its ranking on the prestigious Deloitte & Touche Technology Fast 500, ProCyte’s leaders have proven that they have the vision and the fortitude to excel in the highly competitive technology industry," said Mark A. Evans, managing director of Deloitte & Touche’s Technology, Media & Telecommunications Group. "We congratulate ProCyte Corporation on becoming one of the 500 fastest growing technology companies in the United States and Canada."

In addition to ranking on the Deloitte & Touche Technology Fast 500, ProCyte Corporation ranked 17 on the Washington State Technology Fast 50, which is a ranking of the 50 fastest growing technology firms in that region, its second consecutive year on the list.

The Fast 500 list is compiled from three sources: Deloitte & Touche’s 20 regional North American Fast 50 programs, nominations submitted directly to the Fast 500, and public company database research. To qualify for the Fast 500, companies must have had 1997 operating revenues of at least $50,000 USD and $75,000 CD, for United States and Canada respectively, must be public or private companies headquartered in North America, and be "technology companies" defined as companies that own proprietary technology that contributes to a significant portion of the company’s operating revenues or devote a high percentage of effort to research and development of technology.

Technology Fast 500 winners are invited to an exclusive CEO Summit held each spring. The CEO Summit, now in its fifth year, is designed to address the unique business challenges facing these super-charged technology companies.

ProCyte Corporation develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. The Company sells directly to Dermatologists and Plastic Surgeons and through licenses with strategic partners into the consumer market, including its long-term worldwide license agreement with Neutrogena^®, a Johnson & Johnson company. ProCyte’s products include Neova^® Anti-Aging Skin Care, Complex Cu₃^® Post-Procedure Skin Care, GraftCyte^® Hair Transplant Care and Tricomin^® Advanced Care for Thinning Hair. Additional information is available by visiting our website at www.procyte.com.

Deloitte & Touche, one of the nation’s leading professional services firms, provides assurance and advisory, tax, and management consulting services through nearly 30,000 people in more than 100 U.S. cities. The firm is dedicated to helping its clients and its people excel. Known as an employer of choice for innovative human resources programs, Deloitte & Touche has been recognized as one of the "100 Best Companies to Work for in America" by Fortune magazine for five consecutive years. Deloitte & Touche refers to Deloitte & Touche LLP and its related entities. Deloitte & Touche is the U.S. national practice of Deloitte Touche Tohmatsu. Deloitte Touche Tohmatsu is a Swiss Verein, and each of its national practices is a separate and independent legal entity. For more information, please visit Deloitte & Touche’s website at www.deloitte.com.

This release may contain forward-looking statements relating to the research, development, commercialization, production, marketing and distribution of the Company's products and future operating results that are subject to certain risks and uncertainties which could cause actual results to differ materially from those projected. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. [Factors that could affect the Company’s actual results include its ability to develop, commercialize and produce new products, the market acceptance of existing and potential future products, the availability, cost and timely delivery of materials and services from and performance of third party suppliers, manufacturers, distributors, licensees and other collaborative partners, the satisfaction of regulatory requirements, and the receipt, timing, terms and conditions of required regulatory approvals.] Reference is made to the Company’s latest Quarterly Report on Form 10Q or Form 10K filed with the Securities and Exchange Commission for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.